XBiotech Stock Price, News & Analysis (NASDAQ:XBIT)

$4.16 0.03 (0.73 %)
(As of 01/16/2018 10:52 AM ET)
Previous Close$4.13
Today's Range$4.02 - $4.18
52-Week Range$2.77 - $20.18
Volume70,100 shs
Average Volume53,678 shs
Market Capitalization$147.42 million
P/E Ratio-2.55
Dividend YieldN/A
Beta0.54

About XBiotech (NASDAQ:XBIT)

XBiotech logoXBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Debt-to-Equity RatioN/A
Current Ratio11.51%
Quick Ratio11.51%

Price-To-Earnings

Trailing P/E Ratio-2.5521472392638
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book2.29

Profitability

Trailing EPS($1.63)
Net Income$-52,760,000.00
Net MarginsN/A
Return on Equity-60.07%
Return on Assets-55.80%

Miscellaneous

Employees106
Outstanding Shares35,440,000

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) announced its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View XBiotech's Earnings History.

When will XBiotech make its next earnings announcement?

XBiotech is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for XBiotech.

Where is XBiotech's stock going? Where will XBiotech's stock price be in 2018?

2 equities research analysts have issued 12-month target prices for XBiotech's stock. Their forecasts range from $13.00 to $13.00. On average, they anticipate XBiotech's share price to reach $13.00 in the next twelve months. View Analyst Ratings for XBiotech.

Are investors shorting XBiotech?

XBiotech saw a decline in short interest in the month of November. As of November 30th, there was short interest totalling 6,021,175 shares, a decline of 2.2% from the November 15th total of 6,158,708 shares. Based on an average daily volume of 67,965 shares, the short-interest ratio is presently 88.6 days. Currently, 38.1% of the company's shares are sold short.

Who are some of XBiotech's key competitors?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:

  • John Simard, Chairman of the Board, President, Chief Executive Officer, Founder (Age 54)
  • Scott Whitehurst, Chief Financial Officer (Age 50)
  • Kelly R. Thornburg, Senior Vice President - Operations (Age 52)
  • Queena Han, Vice President - Finance, Human Resources (Age 49)
  • David J Combs, Vice President - Manufacturing (Age 36)
  • Norma I Gonzalez, Vice President - Quality (Age 58)
  • Dawn McCollough, Vice President of Clinical Operations
  • Sushma Shivaswamy, Vice President - Research & Development (Age 37)
  • Michael D Stecher, Medical Director (Age 38)
  • Daniel L. Vasella M.D., Lead Independent Director (Age 64)

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

How do I buy XBiotech stock?

Shares of XBiotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBiotech stock can currently be purchased for approximately $4.16.

How big of a company is XBiotech?

XBiotech has a market capitalization of $147.42 million. The biopharmaceutical company earns $-52,760,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. XBiotech employs 106 workers across the globe.

How can I contact XBiotech?

XBiotech's mailing address is 8201 E. RIVERSIDE DRIVE BUILDING 4 SUITE 100, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (XBIT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

XBiotech (NASDAQ:XBIT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.00$13.00$13.00
Price Target Upside: 27.33% upside27.33% upside27.33% upside27.33% upside

XBiotech (NASDAQ:XBIT) Consensus Price Target History

Price Target History for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ:XBIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
4/21/2017Noble FinancialReiterated RatingBuy -> Hold$13.00HighView Rating Details
(Data available from 1/16/2016 forward)

Earnings

XBiotech (NASDAQ:XBIT) Earnings History and Estimates Chart

Earnings by Quarter for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ XBIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
5/10/2017Q1 2017($0.47)($0.32)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.42)($0.51)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.46)($0.38)ViewListenView Earnings Details
8/12/2016Q2 2016($0.35)($0.42)ViewN/AView Earnings Details
5/18/2016Q1 2016($0.39)($0.32)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.35)($0.37)ViewN/AView Earnings Details
11/12/2015Q3($0.21)($0.33)ViewListenView Earnings Details
8/14/2015Q2 2015($0.22)ViewN/AView Earnings Details
5/27/2015Q1 2015($0.29)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

XBiotech (NASDAQ:XBIT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for XBiotech (NASDAQ:XBIT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

XBiotech (NASDAQ XBIT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 10.96%
Insider Trades by Quarter for XBiotech (NASDAQ:XBIT)
Institutional Ownership by Quarter for XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ XBIT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2016Queena HanVPSell19,573$15.00$293,595.0019,573View SEC Filing  
9/8/2016Queena HanVPSell427$15.00$6,405.00427View SEC Filing  
5/26/2016W Thorpe MckenzieDirectorBuy20,000$13.96$279,200.003,898,600View SEC Filing  
5/20/2016W Thorpe MckenzieDirectorBuy1,500$13.75$20,625.003,898,600View SEC Filing  
12/22/2015Queena HanVPSell30,000$10.39$311,700.00View SEC Filing  
11/16/2015Michael StecherDirectorSell1,800$14.00$25,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

XBiotech (NASDAQ XBIT) News Headlines

Source:
DateHeadline
Financial Analysis: XBiotech (XBIT) vs. Its PeersFinancial Analysis: XBiotech (XBIT) vs. Its Peers
www.americanbankingnews.com - January 7 at 7:28 AM
Winners, losers: The 5 best and 5 worst performing Austin-area stocks of 2017Winners, losers: The 5 best and 5 worst performing Austin-area stocks of 2017
www.bizjournals.com - January 6 at 10:25 AM
Cynapsus Therapeutics (CYNA) & XBiotech (XBIT) Head-To-Head ComparisonCynapsus Therapeutics (CYNA) & XBiotech (XBIT) Head-To-Head Comparison
www.americanbankingnews.com - January 3 at 5:34 PM
Analyzing XBiotech (XBIT) and Its CompetitorsAnalyzing XBiotech (XBIT) and Its Competitors
www.americanbankingnews.com - January 1 at 3:28 AM
Reviewing XBiotech (XBIT) & The CompetitionReviewing XBiotech (XBIT) & The Competition
www.americanbankingnews.com - December 29 at 7:24 PM
Financial Contrast: XBiotech (XBIT) vs. Its RivalsFinancial Contrast: XBiotech (XBIT) vs. Its Rivals
www.americanbankingnews.com - December 19 at 7:10 PM
Short Interest in XBiotech Inc. (XBIT) Decreases By 2.2%Short Interest in XBiotech Inc. (XBIT) Decreases By 2.2%
www.americanbankingnews.com - December 18 at 4:36 PM
Contrasting XBiotech (XBIT) & Revance Therapeutics (RVNC)Contrasting XBiotech (XBIT) & Revance Therapeutics (RVNC)
www.americanbankingnews.com - December 17 at 1:50 AM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - December 11 at 4:38 PM
Critical Analysis: XBiotech (XBIT) & Its RivalsCritical Analysis: XBiotech (XBIT) & Its Rivals
www.americanbankingnews.com - December 11 at 8:08 AM
Critical Review: XBiotech (XBIT) versus Its PeersCritical Review: XBiotech (XBIT) versus Its Peers
www.americanbankingnews.com - December 9 at 7:18 PM
XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 StudyXBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study
www.streetinsider.com - December 5 at 4:25 PM
XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study - StreetInsider.comXBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study - StreetInsider.com
www.streetinsider.com - December 4 at 4:27 PM
Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark ... - PR Newswire (press release)
www.prnewswire.com - November 18 at 10:26 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - November 18 at 10:26 AM
XBiotech (XBIT) Announces Presentation of Novel Findings for MABp1 in Prevention of Coronary Thrombosis at AHA - StreetInsider.comXBiotech (XBIT) Announces Presentation of Novel Findings for MABp1 in Prevention of Coronary Thrombosis at AHA - StreetInsider.com
www.streetinsider.com - November 16 at 8:57 AM
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech ...XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech ...
www.businesswire.com - November 9 at 10:17 AM
XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
finance.yahoo.com - November 9 at 10:17 AM
XBiotech (XBIT) Says Its MABp1 to be Featured in Oral Presentation ... - StreetInsider.comXBiotech (XBIT) Says Its MABp1 to be Featured in Oral Presentation ... - StreetInsider.com
www.streetinsider.com - November 5 at 8:19 AM
XBiotechs MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific SessionsXBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
feeds.benzinga.com - November 3 at 12:58 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered ... - GlobeNewswire (press release)
globenewswire.com - October 27 at 10:09 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBITSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBIT
finance.yahoo.com - October 27 at 7:43 AM
XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 Combo with Onivyde and 5-fluorouracil/folinic acid for Treatment of Pancreatic CancerXBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 Combo with Onivyde and 5-fluorouracil/folinic acid for Treatment of Pancreatic Cancer
www.streetinsider.com - October 20 at 10:33 AM
XBiotech Enters Oversold Territory (XBIT)XBiotech Enters Oversold Territory (XBIT)
www.thestreet.com - October 20 at 10:33 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBITINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
finance.yahoo.com - October 20 at 10:33 AM
XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 ... - StreetInsider.comXBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 ... - StreetInsider.com
www.streetinsider.com - October 18 at 9:49 PM
Comparing Acer Therapeutics (ACER) & XBiotech (XBIT)Comparing Acer Therapeutics (ACER) & XBiotech (XBIT)
www.americanbankingnews.com - October 18 at 2:24 PM
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerXBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - October 18 at 10:53 AM
XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory BoardXBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
finance.yahoo.com - October 3 at 3:31 PM
XBiotech to Present at Cantor Fitzgeralds Global Healthcare ConferenceXBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
finance.yahoo.com - September 23 at 12:14 PM
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination withXBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with
www.nasdaq.com - September 20 at 11:22 AM
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerXBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - September 20 at 11:22 AM
Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc.Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc.
www.thestreet.com - September 19 at 9:47 AM
Contrasting XBiotech (XBIT) & Lexicon Pharmaceuticals (LXRX)Contrasting XBiotech (XBIT) & Lexicon Pharmaceuticals (LXRX)
www.americanbankingnews.com - September 15 at 4:34 AM
XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis ... - GlobeNewswire (press release)XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis ... - GlobeNewswire (press release)
globenewswire.com - September 7 at 11:29 AM
XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaXBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
finance.yahoo.com - September 7 at 11:29 AM
XBiotech Inc. (NASDAQ:XBIT) Scheduled to Post Quarterly Earnings on MondayXBiotech Inc. (NASDAQ:XBIT) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 7 at 7:08 AM
Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - July 12 at 9:28 AM
Stock market climbs as health-care shares extend rallyStock market climbs as health-care shares extend rally
www.marketwatch.com - June 22 at 2:50 PM
Biotech Movers: Coherus, XBiotech, Flexion - TheStreet.comBiotech Movers: Coherus, XBiotech, Flexion - TheStreet.com
www.thestreet.com - June 12 at 8:13 PM
BUZZ-US STOCKS ON THE MOVE-GE, tech stocks, Coherus, XBiotech - NasdaqBUZZ-US STOCKS ON THE MOVE-GE, tech stocks, Coherus, XBiotech - Nasdaq
www.nasdaq.com - June 12 at 8:13 PM
XBiotech (XBIT) Presents Phase III Findings for Antibody Therapy for Colorectal Cancer at ASCOXBiotech (XBIT) Presents Phase III Findings for Antibody Therapy for Colorectal Cancer at ASCO
www.streetinsider.com - June 3 at 2:35 AM
Notable Thursday Option Activity: XBIT, BOX, PBYINotable Thursday Option Activity: XBIT, BOX, PBYI
www.nasdaq.com - June 3 at 2:35 AM
After-Hours Stock Movers 05/18: (SPWH) (ADSK) (MCK) Higher; (XBIT) (HALO) (GSBD) Lower (more...)After-Hours Stock Movers 05/18: (SPWH) (ADSK) (MCK) Higher; (XBIT) (HALO) (GSBD) Lower (more...)
www.streetinsider.com - May 19 at 1:52 PM
XBiotechs stock plummets after cancer treatment receives disappointing review panel voteXBiotech's stock plummets after cancer treatment receives disappointing review panel vote
www.marketwatch.com - April 22 at 9:16 AM
XBiotech (XBIT) Announces EMA Negative Trend Vote Related to MAA for Candidate Antibody for Treatment of Colorectal CancerXBiotech (XBIT) Announces EMA Negative 'Trend' Vote Related to MAA for Candidate Antibody for Treatment of Colorectal Cancer
www.streetinsider.com - April 22 at 9:16 AM
Why XBiotech Inc. Got Crushed TodayWhy XBiotech Inc. Got Crushed Today
www.fool.com - April 21 at 2:26 PM
XBiotech Announces Additions To Its Scientific Advisory Board - GlobeNewswire (press release)XBiotech Announces Additions To Its Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - April 12 at 8:45 AM
XBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus InfectionsXBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus Infections
www.nasdaq.com - April 4 at 4:51 AM
[video]XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About[video]XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About
www.thestreet.com - April 4 at 4:51 AM

SEC Filings

XBiotech (NASDAQ:XBIT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

XBiotech (NASDAQ:XBIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

XBiotech (NASDAQ XBIT) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.